Effects of verteporfin on alleviating bleomycin-induced pulmonary fibrosis
Objective To investigate the therapeutic effect and mechanisms of verteporfin(VP)on pulmonary fibrosis mice.Methods The pulmonary fibrosis models were established by intra-tracheal injections of bleomycin(BLM)into C57BL/6 mice.VP(100 mg·kg-1)treatment began on the 8th day after BLM injection,and intraperitoneal injections were given every 3 days for two weeks.The mice were executed on the 21st day.The wet weight of the lungs and the rate of weight change were recorded;the fibrotic foci and collagen deposition in the lungs were observed by HE staining and Masson staining;the hydroxyproline(HYP)levels in the lung tissues were measured by an HYP kit;the mRNA levels of Alpha-smooth muscle actin(α-SMA),the Yes-associated protein(YAP)and interleukin-11(IL-11)were measured by q-PCR;the protein levels of Collagen Ⅰ,α-SMA,YAP,and NF-κB p65 were measured by Western blot;the IL-11 levels in lung tissue homogenates were measured by an ELISA kit.Results After VP treatments,the rate of body weight change and the lung-body ratio of mice were reduced;the fibrotic foci and collagen deposition were improved in HE staining and Masson staining;the levels of HYP,Collagen Ⅰand α-SMA in lung tissues were reduced;VP also decreased the expressions of YAP,NF-κB p65 and IL-11 in lung tissues.Conclusion VP alleviates BLM-induced pulmonary fibrosis in mice,and its effects may be related to the downregulation of IL-11.